1. Committee for Medicinal Products for Human Use (2011) Reflection paper on the need for active control in therapeutic areas where use of placebo is deemed ethical and one or more established medicines are available. EMA/759784/2010. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/01/WC500100710.pdf . Accessed 17 May 2011
2. Garattini S, Bertele’ V (2007) Non-inferiority trials are unethical because they disregard patients’ interests. Lancet 370(9602):1875–1877. doi: 10.1016/S0140-6736(07)61604-3
3. World Medical Association (1964–2008) (2008) The Declaration of Helsinki. Available at: http://www.wma.net/en/30publications/10policies/b3/ . Accessed 18 July 2011
4. DHHS Food and Drug Administration. 21 CFR part 312 (2008) Human subject protection; foreign clinical studies not conducted under an investigational new drug application. Final rule 28 April 2008, effective, October 27 2008. Available at: http://www.regulations.gov/fdmspublic/component/main?main=DocumentDetail&o=0900006480537f08 . Accessed 18 July 2011
5. Barbui C, Cipriani A, Lintas C, Bertele’ V, Garattini S (2007) CNS drugs approved by the centralised European procedure: true innovation or dangerous stagnation? Psychopharmacology (Berl) 190(2):265–268. doi: 10.1007/s00213-006-0629-3